Moderate

VTE anticoagulation - DOAC selection & duration

VTE DOAC choice · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

After confirming venous thromboembolism, the key decisions are agent choice (usually a direct oral anticoagulant), appropriate dosing phases, and treatment duration determined by whether the event was provoked, unprovoked or cancer-associated.

Red flags

  • Haemodynamic instability (massive PE - consider thrombolysis)
  • Active major bleeding
  • Severe renal impairment (CrCl <15-30) limiting DOAC use
  • Triple-positive antiphospholipid syndrome (DOAC contraindicated)
  • Recurrent VTE despite compliant anticoagulation

Assessment

Differential diagnosis

  • Provoked VTE (surgery, immobility, oestrogen)
  • Unprovoked VTE
  • Cancer-associated thrombosis
  • Antiphospholipid syndrome
  • Recurrent VTE on anticoagulation

Investigations

  • Confirm VTE (Doppler/CTPA) and assess clot burden
  • FBC, renal and liver function (dose/agent selection)
  • Weight and bleeding risk assessment
  • Pregnancy test in women of childbearing age
  • Consider cancer assessment in unprovoked VTE (history, exam, age-appropriate screening)
  • Antiphospholipid testing if clinically indicated (especially recurrent/arterial)

Management

  • Confirm diagnosis and ensure the patient is haemodynamically stable (exclude high-risk PE needing thrombolysis)
  • Assess renal function, bleeding risk, weight, drug interactions and patient preference
  • Choose a DOAC first line for most non-cancer VTE (NICE preference: apixaban or rivaroxaban)
  • Use the correct loading phase: higher-dose lead-in for apixaban and rivaroxaban, or 5 days LMWH before dabigatran/edoxaban
  • Use LMWH in pregnancy, severe renal impairment, antiphospholipid syndrome (avoid DOACs, use warfarin), and extremes of weight where evidence is limited
  • For cancer-associated VTE offer a DOAC (edoxaban/rivaroxaban/apixaban) or LMWH, weighing GI/urothelial bleeding risk
  • Treat provoked VTE with a transient risk factor for 3 months
  • Continue beyond 3 months (often long term) for unprovoked VTE, recurrent events, or active cancer, balancing bleeding risk
  • Consider reduced-dose apixaban or rivaroxaban for extended prophylaxis after initial treatment
  • Review periodically, reassess bleeding risk, and ensure adherence and monitoring of renal function

Drugs & doses

Apixaban 10 mg PO twice daily for 7 days then 5 mg twice daily (2.5 mg BD for extended phase)
Rivaroxaban 15 mg PO twice daily for 21 days then 20 mg once daily (10-20 mg OD extended)
Edoxaban 60 mg PO once daily after >=5 days LMWH (30 mg if CrCl 15-50 or low weight)
Dabigatran 150 mg PO twice daily after >=5 days LMWH; LMWH e.g. dalteparin/enoxaparin weight-based for cancer/pregnancy

Disposition

Ambulatory management for low-risk DVT/PE; admit high-risk PE; anticoagulation clinic / primary care follow-up with scheduled review.

Complications & pitfalls

  • Major haemorrhage
  • Recurrent VTE
  • Post-thrombotic syndrome
  • Chronic thromboembolic pulmonary hypertension
  • DOAC failure in antiphospholipid syndrome

Exam pearls

  • Apixaban and rivaroxaban need no LMWH lead-in; edoxaban and dabigatran do
  • Avoid DOACs in triple-positive antiphospholipid syndrome - use warfarin
  • Cancer-associated VTE: DOACs are effective but watch GI/urothelial bleeding
  • Unprovoked VTE often warrants indefinite anticoagulation if bleeding risk is acceptable
  • Reassess renal function and bleeding risk at every review

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.